NovoCure Limited (NASDAQ:NVCR) CEO Asaf Danziger sold 274,359 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $18.07, for a total value of $4,957,667.13. Following the completion of the sale, the chief executive officer now directly owns 668,865 shares of the company’s stock, valued at approximately $12,086,390.55. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Asaf Danziger also recently made the following trade(s):

  • On Wednesday, July 5th, Asaf Danziger sold 155,088 shares of NovoCure Limited stock. The shares were sold at an average price of $18.14, for a total value of $2,813,296.32.
  • On Thursday, July 6th, Asaf Danziger sold 160,138 shares of NovoCure Limited stock. The shares were sold at an average price of $18.14, for a total value of $2,904,903.32.
  • On Monday, June 19th, Asaf Danziger sold 124,720 shares of NovoCure Limited stock. The shares were sold at an average price of $15.51, for a total value of $1,934,407.20.
  • On Friday, June 16th, Asaf Danziger sold 42,457 shares of NovoCure Limited stock. The shares were sold at an average price of $15.15, for a total value of $643,223.55.
  • On Wednesday, June 14th, Asaf Danziger sold 94,102 shares of NovoCure Limited stock. The shares were sold at an average price of $15.22, for a total value of $1,432,232.44.
  • On Monday, June 12th, Asaf Danziger sold 180,601 shares of NovoCure Limited stock. The shares were sold at an average price of $15.13, for a total value of $2,732,493.13.

NovoCure Limited (NVCR) traded up 10.22% on Tuesday, reaching $19.95. The company’s stock had a trading volume of 3,442,803 shares. NovoCure Limited has a one year low of $5.95 and a one year high of $20.85. The firm has a 50-day moving average of $14.10 and a 200-day moving average of $9.87. The company’s market capitalization is $1.76 billion.

NovoCure Limited (NASDAQ:NVCR) last announced its earnings results on Thursday, April 27th. The medical equipment provider reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.04. NovoCure Limited had a negative return on equity of 74.31% and a negative net margin of 109.30%. The business had revenue of $34.88 million during the quarter, compared to analyst estimates of $39.46 million. Analysts predict that NovoCure Limited will post ($0.80) EPS for the current year.

TRADEMARK VIOLATION WARNING: “NovoCure Limited (NVCR) CEO Sells $4,957,667.13 in Stock” was reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/07/11/novocure-limited-nvcr-ceo-sells-4957667-13-in-stock.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in shares of NovoCure Limited by 12.0% in the first quarter. Vanguard Group Inc. now owns 3,047,940 shares of the medical equipment provider’s stock valued at $24,688,000 after buying an additional 325,512 shares during the period. Peregrine Capital Management LLC raised its position in shares of NovoCure Limited by 7.4% in the first quarter. Peregrine Capital Management LLC now owns 1,210,934 shares of the medical equipment provider’s stock valued at $10,051,000 after buying an additional 83,448 shares during the period. Bank of New York Mellon Corp raised its position in shares of NovoCure Limited by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 173,523 shares of the medical equipment provider’s stock valued at $1,406,000 after buying an additional 2,480 shares during the period. Geode Capital Management LLC raised its position in shares of NovoCure Limited by 14.6% in the first quarter. Geode Capital Management LLC now owns 128,632 shares of the medical equipment provider’s stock valued at $1,041,000 after buying an additional 16,411 shares during the period. Finally, River & Mercantile Asset Management LLP acquired a new position in shares of NovoCure Limited during the first quarter valued at about $937,000. Institutional investors and hedge funds own 24.19% of the company’s stock.

A number of research firms have commented on NVCR. Zacks Investment Research raised NovoCure Limited from a “sell” rating to a “buy” rating and set a $19.00 price target for the company in a research report on Thursday, June 29th. ValuEngine raised NovoCure Limited from a “sell” rating to a “hold” rating in a research report on Saturday, June 3rd. Wells Fargo & Company raised NovoCure Limited from a “market perform” rating to an “outperform” rating and set a $15.00 price target for the company in a research report on Wednesday, May 24th. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $14.00 price target on shares of NovoCure Limited in a research report on Monday, May 1st. Finally, Deutsche Bank AG upped their price target on NovoCure Limited from $10.00 to $11.00 and gave the company a “hold” rating in a research report on Friday, April 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $17.00.

About NovoCure Limited

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with MarketBeat.com's FREE daily email newsletter.